WeTrials
Recruiting

A Phase 1/2 Open-label Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

What is this study?

This clinical trial is testing an experimental medication called Debio 0123 combined with standard brain tumor treatments for adults with glioblastoma. The goal is to find the safest and most effective dose to help fight this aggressive type of brain tumor.

Who can participate?

You may be able to join if you are 18 or older, have been diagnosed with a specific type of brain tumor, and have healthy organ function. You also need to be able to follow the study schedule and agree to the required tests.

What will happen?

Participants will receive the study medication along with standard treatments like chemotherapy or radiation, depending on the study phase. Doctors will closely monitor your health, safety, and how your body responds through regular clinic visits and lab tests.

Where and when?

The study is currently recruiting participants at locations in major cities like Chicago and New York. Speak with your care team to see if one of these locations works for you.

Key Points
  • 1Tests a new targeted cancer drug called Debio 0123 with standard treatments
  • 2Open to adults aged 18 and older with specific brain tumors
  • 3Currently actively recruiting participants in the United States

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeAstrocytoma, Grade III

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.